Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 198

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 198
---
 contain a contractual provision stating that all questions concerning the construction, validity, enforcement and interpretation of the Regulation A Warrants are governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law.

This summary of the Regulation A Warrants is not complete, and is qualified in its entirety by, the full text of the Regulation A Warrants and Warrant Agency Agreement in respect of the Regulation A Warrants, copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus forms a part and are incorporated in this prospectus by reference.

June 2030 Warrants

As of November 7, 2025, we had 2,260,000 June 2030 Warrants outstanding. Each warrant is exercisable for one common share at an exercise price of $3.10. The June 2030 Warrants were issued on June 2, 2025 in connection with our May 2025 Unit Offering and are exercisable at any time for a period of five years following the date of issuance, expiring on or prior to 5:00 pm ET on June 3, 2030.

The number of June 2030 Warrants outstanding, and the exercise price of those securities, will be adjusted proportionately in the event of a consolidation or share split of our common shares, a recapitalization or reclassification of our common shares, payment of dividends or distributions in common shares to our common share holders, or similar transactions. In the event that the Company effects a rights offering to its common share holders or a pro rata distribution of its assets among its common share holders, then the holders of the June 2030 Warrants will have the right to participate in such distribution and rights offering to the extent of their pro rata share of the Company's outstanding common shares assuming they owned the number of common shares issuable upon the exercise of their June 2030 Warrants. In the event of a "Fundamental Transaction" by the Company, such as a merger or consolidation of it with another company, the sale or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, a purchase offer, tender offer or exchange offer, or any reclassification, reorganization or recapitalization of the common shares, then the June 2030 Warrant holders will have the right to receive, for each common share issuable upon the exercise of a June